Prasugrel reduces agonists′ inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel

Cardiovascular Therapeutics

Volumn 31, Issue 5, 2013, Pages

  Gremmel, Thomas ^a   Eslam, Roza Badr ^a   Koppensteiner, Renate ^a   Lang, Irene M ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clopidogrel; Monocyte platelet aggregates; Platelet activation; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN; PRASUGREL; PROTON PUMP INHIBITOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL INTERACTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE PLATELET INTERACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE;

CLOPIDOGREL; MONOCYTE-PLATELET AGGREGATES; PLATELET ACTIVATION; PRASUGREL;

AGED; BLOOD PLATELETS; CELL COMMUNICATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; P-SELECTIN; PEPTIDE FRAGMENTS; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THIOPHENES; TICLOPIDINE;

EID: 84878379969     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12021     Document Type: Article

References (31)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 2006;27:1010-1012.
3. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010;8:37-42.
4. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:1511-1515.
5. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-1977.
6. Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010;55:1139-1146.
7. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-189.
8. Gremmel T, Kopp CW, Moertl D, et al. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thromb Res 2012;129:616-622.
9. Gremmel T, Kopp CW, Seidinger D, et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol 2011. DOI: 10.1016/j.ijcard.2011.10.010.
10. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
11. Cattaneo M. New P2Y12 blockers. J Thromb Haemost 2009;7(Suppl 1):262-265.
12. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
13. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
14. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
15. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-473.
16. Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002;23:1771-1779.
17. Gremmel T, Calatzis A, Steiner S, et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets 2010;21:515-521.
18. Badr Eslam R, Lang IM, Koppensteiner R, Calatzis A, Panzer S, Gremmel T. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol 2012. DOI: 10.1016/j.ijcard.2012.09.103.
19. Eslam RB, Reiter N, Kaider A, Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J 2009;30:1831-1836.
20. Subramanian H, Gambaryan S, Panzer S, Gremmel T, Walter U, Mannhalter C. The Thr715Pro variant impairs terminal glycosylation of P-selectin. Thromb Haemost 2012;108:963-972.
21. Gurbel PA, Erlinge D, Ohman EM, et al. for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012. DOI: 10.1001/jama.2012.17312.
22. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005;25:1321-1324.
23. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004;92:459-466.
24. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
25. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
26. Brambilla M, Camera M, Colnago D, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 2008;28:947-953.
27. Gremmel T, Kopp CW, Seidinger D, Giurgea GA, Koppensteiner R, Steiner S, Panzer S. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. Atherosclerosis 2009;207:608-613.
28. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33.
29. Morrow DA, Braunwald E, Bonaca MP, et al. Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-1413.
30. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-315.
31. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011;106:211-218.